Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Congratulations to Dr. Philippe Bedard who was recently honoured with the 17th annual Michaele C. Christian Oncology Drug Development Award at the NCI CTEP Early Drug Development Meeting.
Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.
Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood (circulating tumour DNA – ctDNA) as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour.
CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants.